Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263.40M | $78.50M | $131.40M | $53.60M | $25.90M | $42.98M | $14.32M | $7.58M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $263.40M | $78.50M | $131.40M | $53.60M | $25.90M | $42.98M | $14.32M | $7.58M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $513.60M | $480.00M | $394.60M | $242.00M | $146.70M | $94.50M | $58.13M | $32.34M |
| Operating Income | $-250.20M | $-401.50M | $-263.20M | $-188.40M | $-120.80M | $-51.52M | $-43.80M | $-24.76M |
| Operating Margin | -94.99% | -511.46% | -200.30% | -351.49% | -466.41% | -119.89% | -305.80% | -326.70% |
| Net Income | $-198.90M | $-367.30M | $-282.50M | $-191.00M | $-119.30M | $-70.29M | $-41.48M | $-24.05M |
| Net Margin | -75.51% | -467.90% | -214.99% | -356.34% | -460.62% | -163.56% | -289.59% | -317.32% |
| EPS (Basic) | $-2.77 | $-6.62 | $-5.31 | $-3.82 | $-3.02 | $-1.89 | $-1.31 | $-1.38 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |